Tepnel Pharma Services expands portfolio to include companion diagnostic development

Published: 23-Feb-2015

New service offers customers flexibility and state-of-the-art technologies


Tepnel Pharma Services, the contract research organisation arm of Hologic, a developer of diagnostic products, medical imaging systems and surgical products, has expanded its portfolio of services to include companion diagnostic development. This new service will build on Tepnel’s reputation as a world class contract research organisation specialising in molecular genetic services, the company said.

The growth in companion diagnostic development has been significant as costs associated with drug discovery, development and launch continue to rise, and as demand for patient-tailored solutions for disease increases, the company said. Companion diagnostic development has the potential to decrease drug development time and expense, while at the same time enhancing therapeutic efficacy. Tepnel will use both its proprietary and non-proprietary technology platforms in this new service.

‘Companion diagnostic development is a valuable addition to Tepnel’s portfolio of services and an exciting next step in the evolution of our genomics business,’ said David Scott, Senior Director, Tepnel Pharma Services. ‘Our knowledge and understanding of the drug development process, coupled with Hologic’s expertise in the diagnostic industry, create a service platform that will support each phase of our customers’ development initiatives. Our new service offers our customers flexibility, and state-of-the-art technologies that should result in the availability of diagnostic tools designed to improve patient outcomes while meeting the economic demands of healthcare systems.’

You may also like